opevesostat + dexamethasone + fludrocortisone

This is a **combination therapy** primarily used in clinical trials for **metastatic castration-resistant prostate cancer (mCRPC)**. It consists of opevesostat (MK-5684), a novel oral small molecule targeting the androgen pathway; dexamethasone, a potent synthetic glucocorticoid used to suppress inflammation and reduce the risk of adrenal insufficiency; and fludrocortisone, a synthetic mineralocorticoid for hormone replacement. Opevesostat acts as a next-generation hormonal agent, distinct from earlier agents that lower testosterone, and is typically administered with dexamethasone and fludrocortisone to balance steroid suppression and minimize toxicity. The combination is designed to maximally suppress steroidogenesis while ensuring appropriate glucocorticoid and mineralocorticoid activity, an approach supported by Phase 1 and Phase 3 clinical trials evaluating efficacy and safety for advanced prostate cancer[1][3][5][7][9].

Other names

opevesostat + dexamethasone + fludrocortisoneMK-5684 + dexamethasone + fludrocortisone